Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
AssigneeLudwig Institute for Cancer Research
InventorsVincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Pierre Coulie, Thierry Boon-Falleur, Etienne De Plaen
Life of this patent
Estimating the term…
Abstract
The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or "TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
Claims21
An isolated genomic DNA molecule which encodes a tumor rejection antigen precursor and which hybridizes to a nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO:
- 1, under Southern hybridization conditions.
An isolated nucleic acid molecule which encodes a tumor rejection antigen precursor having an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:
- 1, SEQ ID NO:
- 2, or SEQ ID NO:
- 3.
An isolated nucleic acid molecule, the nucleotide sequence of which consists of the nucleotide sequence of SEQ ID NO:
- 10 or SEQ ID NO:
- 11.
A method for diagnosing a disorder characterized by expression of a tumor rejection antigen encoded by a nucleic acid molecule which comprises at least one of SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, or SEQ ID NO:
- 12, comprising contacting a sample with at least one nucleic acid probe which hybridizes to mRNA for at least one of SEQ ID NO:
- 1, 2, 3 or 12, and determining hybridization of said nucleic acid probe to an mRNA target as a determination of said disorder.
Dependencies are inferred from the claim text.